Detalles de la búsqueda
1.
Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial.
Nephrol Dial Transplant
; 38(12): 2733-2742, 2023 Nov 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37463054
2.
10 Years of belimumab experience: What have we learnt?
Lupus
; 30(11): 1705-1721, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34238087
3.
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Diabetologia
; 59(2): 266-74, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26577795
4.
MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT.
Lupus Sci Med
; 9(1)2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37017254
5.
The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
Arthritis Res Ther
; 22(1): 102, 2020 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32366280
6.
Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program.
Postgrad Med
; 129(8): 849-857, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29083275
7.
Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
Diabetes Care
; 37(10): 2723-30, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25048383
Resultados
1 -
7
de 7
1
Próxima >
>>